The PCSK9 inhibitors market is witnessing significant momentum as these therapies increasingly address unmet clinical needs in hypercholesterolemia management. Driven by advances in biologics and expanding patient populations, the industry size and market growth reflect robust dynamics aligned with evolving treatment paradigms in cardiovascular disease.Market Size and Overview The PCSK9...